InvestorsHub Logo
Post# of 251527
Next 10
Followers 826
Posts 119431
Boards Moderated 16
Alias Born 09/05/2002

Re: DewDiligence post# 180231

Thursday, 09/25/2014 10:05:17 AM

Thursday, September 25, 2014 10:05:17 AM

Post# of 251527
Announced FoB Collaborations

[Added entries for EPRS-Livzon and EPRS-Ranbaxy.]


Items are shown in reverse chronological order. This table does not purport to be exhaustive.


Date Targets Geography iHub References

EPRS-Livzon 9/14 5 mAbs China #msg-106600322
NeuClone-Serum Inst 7/14 10 mAbs global #msg-104136710
Liomont-Oncobiolgcs 6/14 2 mAbs Mexico #msg-103754486
PlantForm-PhrmaPrxs 6/14 Avastin+ Brazil #msg-103576633
Lupin-Yoshindo 4/14 Enbrel+ Japan #msg-101018361
EPRS-Ranbaxy 1/14 Remicade Asia/Africa #msg-95745192
BAX-Coherus 9/13 Enbrel ex-US #msg-91645674
Oncobiolgcs-Huahai 5/13 # global #msg-87734336,#msg-87744882
Strides-Pfenex 4/13 Betaseron global #msg-87014470
MRK-Samsng/BIIB 2/13 @ Europe+ #msg-84781042,#msg-69629103,#msg-95065880
Catalent-UMN 12/12 various Asia #msg-82556713
Merck KGaA-RDY 6/12 oncology global #msg-76359649
Daiichi-Coherus 5/12 * Asia #msg-75397629
Fujifilm-Kyowa 3/12 Humira unspecified #msg-73800486
ACT-Bioton 2/12 insulin US & Europe #msg-74987123
ACT-AMGN 12/11 † global #msg-70097496,#msg-84340328
BAX-MNTA 12/11 ‡ global #msg-70212854,#msg-70258421
HSP-Celltrion 10/09 z global #msg-84519981,#msg-77816122
MYL-Biocon 6/09 x global #msg-72421544,#msg-84561737
Procognia-UTR n/a Humira unspecified #msg-84340976

*Enbrel and Rituxan.

†Humira, Remicade, Herceptin, Avastin, Rituxan, Erbitux; excludes AMGN FoB’s for AMGN’s branded drugs.

‡Three products in development: 2 auto-immune and 1 oncology—my guesses are Humira, Orenica, Erbitux; may include up to 6 products eventually.

@ Samsung/BIIB subordinate collaboration known as Samsung Bioepis developing Remicade and Enbrel FoB’s in Europe (#msg-95065880); Rituxan program terminated (#msg-80622249).

#Humira, Rituxan, Avastin, Herceptin.

x Nine products: Herceptin, Neulasta, Avastin, Humira, Enbrel, Lantus, Novolog, Humalog, one undisclosed.

y Rituxan program terminated (#msg-80236315); status of other programs unknown.

z Each company received a distinct EU/CHMP approval for Remicade on 6/28/13; partnership includes seven (other) products: Rituxan, Herceptin, Enbrel, Erbitux, Synagis, Humira, Avastin.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.